Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124004 | 0.97 | LTB4R2 (0.41) | AGTR1AGTR2LTB4R2HDAC3HDAC4 | |
| SCHEMBL4614467 | 0.87 | AGTR1 (0.37) | AGTR1 | |
| Hydrochloric Acid SCHEMBL3954567 | 0.86 | AGTR1 (0.36) | AGTR1 | |
| SCHEMBL13841581 | 0.86 | — | — | |
| SCHEMBL3954386 | 0.86 | LTB4R2 (0.40) | AGTR1AGTR2LTB4R2HDAC3HDAC4 | |
| SCHEMBL13843472 | 0.85 | MTOR (0.37) | AGTR1 | |
| SCHEMBL3954395 | 0.85 | SOAT1 (0.45) | AGTR1LTB4R2HDAC3HDAC4HDAC1 | |
| SCHEMBL3946218 | 0.84 | SOAT1 (0.47) | — | |
| SCHEMBL3127027 | 0.83 | LTB4R2 (0.45) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL3117096 | 0.83 | HDAC6 (0.56) | AGTR1AGTR2LTB4R2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531576-B2 | Biphenyl derivatives | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7531576-B2 | Biphenyl derivatives | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1354871-B1 | BIPHENYL DERIVATIVES | POLA PHARMA INC (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1354871-A1 | BIPHENYL DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | ACAT2, LCAT, NAT1 | AGTR1 249/4885AGTR2 272/4885LTB4R2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.